These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 22100811

  • 1. A novel mechanism for an old drug: amphotericin B in the treatment of visceral leishmaniasis.
    Chattopadhyay A, Jafurulla M.
    Biochem Biophys Res Commun; 2011 Dec 09; 416(1-2):7-12. PubMed ID: 22100811
    [Abstract] [Full Text] [Related]

  • 2. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages.
    Paila YD, Saha B, Chattopadhyay A.
    Biochem Biophys Res Commun; 2010 Aug 27; 399(3):429-33. PubMed ID: 20678487
    [Abstract] [Full Text] [Related]

  • 3. Foamy histiocytes in a patient with visceral leishmaniasis after treatment with liposomal amphotericin B.
    Tavil B, Seçmeer G, Ozen H, Cengiz AB, Unal S, Gürgey A.
    Turk J Pediatr; 2008 Aug 27; 50(1):67-9. PubMed ID: 18365595
    [Abstract] [Full Text] [Related]

  • 4. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
    Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M.
    Clin Infect Dis; 2009 Jan 15; 48(2):e16-22. PubMed ID: 19093811
    [Abstract] [Full Text] [Related]

  • 5. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
    Oliva G, Foglia Manzillo V, Pagano A.
    Parassitologia; 2004 Jun 15; 46(1-2):231-4. PubMed ID: 15305724
    [Abstract] [Full Text] [Related]

  • 6. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients.
    Vigna E, De Vivo A, Gentile M, Morelli R, Lucia E, Mazzone C, Recchia AG, Vianelli N, Morabito F.
    Transpl Infect Dis; 2010 Oct 15; 12(5):428-31. PubMed ID: 20534035
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.
    Corral MJ, Serrano DR, Moreno I, Torrado JJ, Domínguez M, Alunda JM.
    J Antimicrob Chemother; 2014 Dec 15; 69(12):3268-74. PubMed ID: 25096077
    [Abstract] [Full Text] [Related]

  • 9. [A case of antimony resistant kala-azar cured with amphotericin B].
    Chen SB, Yang CM, Zhang CJ.
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun 15; 25(3):inside front page. PubMed ID: 18038767
    [No Abstract] [Full Text] [Related]

  • 10. Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.
    Sharief AH, Gasim Khalil EA, Theander TG, Kharazmi A, Omer SA, Ibrahim ME.
    Exp Parasitol; 2006 Dec 15; 114(4):247-52. PubMed ID: 16716301
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Chitosan coated PluronicF127 micelles for effective delivery of Amphotericin B in experimental visceral leishmaniasis.
    Singh PK, Pawar VK, Jaiswal AK, Singh Y, Srikanth CH, Chaurasia M, Bora HK, Raval K, Meher JG, Gayen JR, Dube A, Chourasia MK.
    Int J Biol Macromol; 2017 Dec 15; 105(Pt 1):1220-1231. PubMed ID: 28780414
    [Abstract] [Full Text] [Related]

  • 13. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
    Rosenthal E, Delaunay P, Jeandel PY, Haas H, Pomares-Estran C, Marty P.
    Med Mal Infect; 2009 Oct 15; 39(10):741-4. PubMed ID: 19783391
    [Abstract] [Full Text] [Related]

  • 14. Visceral leishmaniasis in children: a review.
    Palumbo E.
    Minerva Pediatr; 2010 Aug 15; 62(4):389-95. PubMed ID: 20940672
    [Abstract] [Full Text] [Related]

  • 15. Amphotericin B: A drug of choice for Visceral Leishmaniasis.
    Kumari S, Kumar V, Tiwari RK, Ravidas V, Pandey K, Kumar A.
    Acta Trop; 2022 Nov 15; 235():106661. PubMed ID: 35998680
    [Abstract] [Full Text] [Related]

  • 16. Current scenario of drug development for leishmaniasis.
    Croft SL, Seifert K, Yardley V.
    Indian J Med Res; 2006 Mar 15; 123(3):399-410. PubMed ID: 16778319
    [Abstract] [Full Text] [Related]

  • 17. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
    Wasan KM, Wasan EK, Gershkovich P, Zhu X, Tidwell RR, Werbovetz KA, Clement JG, Thornton SJ.
    J Infect Dis; 2009 Aug 01; 200(3):357-60. PubMed ID: 19545212
    [Abstract] [Full Text] [Related]

  • 18. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J.
    Clin Infect Dis; 2006 Oct 01; 43(7):917-24. PubMed ID: 16941377
    [Abstract] [Full Text] [Related]

  • 19. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp.
    Ruiz HK, Serrano DR, Dea-Ayuela MA, Bilbao-Ramos PE, Bolás-Fernández F, Torrado JJ, Molero G.
    Int J Pharm; 2014 Oct 01; 473(1-2):148-57. PubMed ID: 24998510
    [Abstract] [Full Text] [Related]

  • 20. Cholesterol: a potential therapeutic target in Leishmania infection?
    Pucadyil TJ, Chattopadhyay A.
    Trends Parasitol; 2007 Feb 01; 23(2):49-53. PubMed ID: 17185038
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.